226 related articles for article (PubMed ID: 30095435)
1. Association of characteristics of HBV quasispecies with hepatitis B surface antigen seroconversion after pegylated interferon-α-2a treatment in child patients.
Yang J; Yang G; He H; Ning L; Liu Z; Fu Q; Chen H; Deng H; Wang Z; Luo K
Antivir Ther; 2018; 23(7):567-574. PubMed ID: 30095435
[TBL] [Abstract][Full Text] [Related]
2. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.
Tseng TC; Yu ML; Liu CJ; Lin CL; Huang YW; Hsu CS; Liu CH; Kuo SF; Pan CJ; Yang SS; Su CW; Chen PJ; Chen DS; Kao JH
Antivir Ther; 2011; 16(5):629-37. PubMed ID: 21817184
[TBL] [Abstract][Full Text] [Related]
3. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.
Tangkijvanich P; Komolmit P; Mahachai V; Sa-nguanmoo P; Theamboonlers A; Poovorawan Y
J Clin Virol; 2009 Oct; 46(2):117-23. PubMed ID: 19651540
[TBL] [Abstract][Full Text] [Related]
4. Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion.
Yang HC; Chen CL; Shen YC; Peng CY; Liu CJ; Tseng TC; Su TH; Chuang WL; Yu ML; Dai CY; Liu CH; Chen PJ; Chen DS; Kao JH
Hepatology; 2013 Mar; 57(3):934-43. PubMed ID: 23112104
[TBL] [Abstract][Full Text] [Related]
5. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
[TBL] [Abstract][Full Text] [Related]
6. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
[TBL] [Abstract][Full Text] [Related]
8. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.
Luo X; Yu JX; Xie L; Ma WJ; Wang LH
Ann Hepatol; 2017 November-December,; 16(6):888-892. PubMed ID: 29055925
[TBL] [Abstract][Full Text] [Related]
9. Mutations of pre-core and basal core promoter before and after hepatitis B e antigen seroconversion.
Kamijo N; Matsumoto A; Umemura T; Shibata S; Ichikawa Y; Kimura T; Komatsu M; Tanaka E
World J Gastroenterol; 2015 Jan; 21(2):541-8. PubMed ID: 25593470
[TBL] [Abstract][Full Text] [Related]
10. Next generation sequencing identifies baseline viral mutants associated with treatment response to pegylated interferon in HBeAg-positive chronic hepatitis B.
Chuaypen N; Payungporn S; Poovorawan K; Chotiyaputta W; Piratvisuth T; Tangkijvanich P
Virus Genes; 2019 Oct; 55(5):610-618. PubMed ID: 31359359
[TBL] [Abstract][Full Text] [Related]
11. Effects of interferon alpha therapy on the catalytic domains of the polymerase gene and basal core promoter, precore and core regions of hepatitis B virus.
Chen RY; Bowden S; Desmond PV; Dean J; Locarnini SA
J Gastroenterol Hepatol; 2003 Jun; 18(6):630-7. PubMed ID: 12753143
[TBL] [Abstract][Full Text] [Related]
12. Sequential analysis of hepatitis B virus core promoter and precore regions in cancer survivor patients with chronic hepatitis B before, during and after interferon treatment.
Zampino R; Marrone A; Cirillo G; del Giudice EM; Utili R; Karayiannis P; Liang TJ; Ruggiero G
J Viral Hepat; 2002 May; 9(3):183-8. PubMed ID: 12010505
[TBL] [Abstract][Full Text] [Related]
13. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
14. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
He LT; Ye XG; Zhou XY
World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
[TBL] [Abstract][Full Text] [Related]
15. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.
Sonneveld MJ; Rijckborst V; Zeuzem S; Heathcote EJ; Simon K; Senturk H; Pas SD; Hansen BE; Janssen HL
Hepatology; 2012 Jul; 56(1):67-75. PubMed ID: 22307831
[TBL] [Abstract][Full Text] [Related]
16. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of hepatitis B surface antigen quasispecies during REP 2139-Ca therapy in HBeAg-positive chronic HBV infection.
Usman Z; Mijočević H; Karimzadeh H; Däumer M; Al-Mathab M; Bazinet M; Frishman D; Vaillant A; Roggendorf M
J Viral Hepat; 2019 Dec; 26(12):1454-1464. PubMed ID: 31323705
[TBL] [Abstract][Full Text] [Related]
18. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
[TBL] [Abstract][Full Text] [Related]
19. Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study.
Zhu S; Zhang H; Dong Y; Wang L; Xu Z; Liu W; Gan Y; Tang H; Chen D; Wang F; Zhao P
J Hepatol; 2018 Jun; 68(6):1123-1128. PubMed ID: 29452204
[TBL] [Abstract][Full Text] [Related]
20. Naturally occurring deletion/insertion mutations within HBV whole genome sequences in HBeAg-positive chronic hepatitis B patients are correlated with baseline serum HBsAg and HBeAg levels and might predict a shorter interval to HBeAg loss and seroconversion during antiviral treatment.
Hao R; Xiang K; Peng Y; Hou J; Sun J; Li Y; Su M; Yan L; Zhuang H; Li T
Infect Genet Evol; 2015 Jul; 33():261-8. PubMed ID: 25976382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
